Evans John M.

Evans John M. serves as the CEO of Beam Therapeutics Inc., a company focused on developing transformative medicines through its proprietary base editing technology. His leadership is pivotal in navigating the company's innovative approaches within the healthcare sector. Between October 2, 2024, and July 1, 2026, Evans has reported a total of 32 disclosures, all related to Beam Therapeutics, primarily consisting of sale transactions. The disclosed amounts range from $25.8K to $791.5K, with a significant transaction on February 2, 2026, involving the grant and exercise of options valued at approximately $4.97 million.